摘要
目的 :比较托吡酯与卡马西平治疗躁狂发作的疗效及安全性。方法 :6 0例躁狂发作病人分为 2组 ,托吡酯组 30例给予托吡酯 ,开始剂量 2 5mg·d- 1,2wk内逐渐增加至 10 0～ 4 0 0mg·d- 1;卡马西平组 30例给予卡马西平 ,开始剂量 0 .1g·d- 1,2wk内逐渐增加至 0 .4～ 1.0 g·d- 1,疗程均 6wk。用BRMS评定疗效 ,TESS评定不良反应。结果 :托吡酯组有效率 6 1% ,卡马西平组 6 2 % ,2组疗效无明显差异 (P >0 .0 5 )。托吡酯组常见的不良反应是胃肠症状 ,除体重下降外 ,与卡马西平组无显著差异。结论 :托吡酯治疗躁狂发作安全有效 ,疗效与卡马西平相似。
To compare the therapeutic efficacy and adverse reactions of topiramate and carbamazepine in the treatment of manic episode. METHODS:Sixty inpatients with manic episode were divided into topiramate or carbamazepine group. Thirty patients of topiramate group were treated with topiramate 25 mg·d -1 at first, then increased gradually to 100～400 mg·d -1 for 6 wk. Thirty patients of carbamazepine group were treated with carbamazpine 0.1 g·d -1 at first, then increased gradually to 0.4～1.0 g·d -1 for 6 wk. Efficacy and adverse reactions were evaluated with BRMS and TESS. RESULTS:The effective rate of topiramate group was 61 %, and that of carbamazepine group was 62%( P >0.05 ). The main adverse reactions of topiramate group were gastrointestinal symptoms as same as the carbamazepine group except loss of body weight. CONCLUSION: Topiramate is safe and effective in treatment of manic episode and can be well tolerant as same as carbamazepine.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2003年第11期671-673,共3页
Chinese Journal of New Drugs and Clinical Remedies
